Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer

Takeiwa, Toshihiko; Ikeda, Kazuhiro; Mitobe, Yuichi; Horie‐Inoue, Kuniko; Inoue, Satoshi

doi:10.3390/cancers12061424

Cited by 15 publications

(16 citation statements)

References 128 publications

(225 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These unique properties have been targeted in treating breast and prostate cancers with hormone therapy ( 3 ). However, during long-term hormone therapy, acquired resistance develops in many patients ( 4 ), and there are few effective treatments for hormone-refractory cancers. In addition, from the tumor diagnosis, breast cancers negative for estrogen receptor α (ERα) such as triple-negative breast cancer (TNBC) exhibit no response to hormone therapy ( 5 ).…”

Section: Breast and Prostate Cancersmentioning

confidence: 99%

“…Transcripts that do not encode proteins are called non-coding RNAs, among them those with a length >200 nucleotides are categorized as lncRNAs ( 8 ). LncRNAs exert their function by regulating a variety of intracellular processes, for example, (1) recruiting epigenetic modifiers and transcription factors to the enhancer/promoter of the lncRNA target gene, (2) forming RNA-RNA binding with its target mRNA for mRNA degradation, (3) acting as a decoy, enabling avoidance of the associated protein from transcriptional regulatory regions, and (4) acting as a molecular sponge or as a competitive endogenous RNA (ceRNA) for microRNA ( 4 , 9 – 11 ). In terms of the contribution of lncRNAs to cancer metabolism, characterization of lncRNAs associated with glucose metabolism has proceeded ( 12 , 13 ) probably because the Warburg effect with aerobic glycolysis has been considered as a central event for cancer metabolism.…”

Section: Long Non-coding Rna (Lncrna)mentioning

confidence: 99%

“…Recently, lncRNA functions in other metabolic pathways including mitochondrial oxidative phosphorylation (OXPHOS) and lipid biosynthesis have been reported. Moreover, it has been shown that lncRNAs also modulate hormone sensitivity and resistance in breast and prostate cancers ( 4 , 10 , 14 ). These findings suggest that the metabolism-associated lncRNAs would be new therapeutic targets for hormone-refractory breast and prostate cancers.…”

Section: Long Non-coding Rna (Lncrna)mentioning

confidence: 99%

“…Based on the molecular aspects of lncRNAs, their expressions and functions could be modulated by nucleic acid therapy using antisense oligonucleotide and RNA interference technique, as well as by small-molecule drugs that bind to lncRNAs. Moreover, effector proteins of lncRNAs will be also potential targets for modulating the lncRNA-associated signaling ( 4 , 7 ). In addition, lncRNA delivery and lncRNA-inducing drugs should be important to modify the functions of these lncRNAs.…”

Section: Long Non-coding Rna (Lncrna)mentioning

confidence: 99%

“…LincRNA-p21 is inducible by hypoxia or HIF1α function in breast cancer cells ( 4 ), and binds to HIF1α and its E3 ubiquitin ligase von Hippel-Lindau (VHL), thereby disrupting the VHL-HIF1α interaction. This dissociation attenuates VHL-mediated HIF1α ubiquitination and results in HIF1α stabilization as a positive feedback loop for HIF1α-dependent pathways.…”

Section: Glucose Metabolism and Lncrnamentioning

confidence: 99%

See 4 more Smart Citations

Long Non-coding RNAs Involved in Metabolic Alterations in Breast and Prostate Cancers

et al. 2020

Self Cite

View full text Add to dashboard Cite

Breast and prostate cancers are the most prevalent cancers in females and males, respectively. These cancers exhibit sex hormone dependence and thus, hormonal therapies are used to treat these cancers. However, acquired resistance to hormone therapies is a major clinical problem. In addition, certain portions of these cancers initially exhibit hormone-independence due to the absence of sex hormone receptors. Therefore, precise and profound understanding of the cancer pathophysiology is required to develop novel clinical strategies against breast and prostate cancers. Metabolic reprogramming is currently recognized as one of the hallmarks of cancer, as exemplified by the alteration of glucose metabolism, oxidative phosphorylation, and lipid metabolism. Dysregulation of metabolic enzymes and their regulators such as kinases, transcription factors, and other signaling molecules contributes to metabolic alteration in cancer. Moreover, accumulating lines of evidence reveal that long non-coding RNAs (lncRNAs) regulate cancer development and progression by modulating metabolism. Understanding the mechanism and function of lncRNAs associated with cancer-specific metabolic alteration will therefore provide new knowledge for cancer diagnosis and treatment. This review provides an overview of recent studies regarding the role of lncRNAs in metabolism in breast and prostate cancers, with a focus on both sex hormone-dependent and -independent pathways.

show abstract

Section: Breast and Prostate Cancersmentioning

confidence: 99%

Section: Long Non-coding Rna (Lncrna)mentioning

confidence: 99%

Section: Long Non-coding Rna (Lncrna)mentioning

confidence: 99%

Section: Long Non-coding Rna (Lncrna)mentioning

confidence: 99%

Section: Glucose Metabolism and Lncrnamentioning

confidence: 99%

See 3 more Smart Citations

Long Non-coding RNAs Involved in Metabolic Alterations in Breast and Prostate Cancers

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Long non-coding RNA A1BG-AS1 promotes tumorigenesis in breast cancer by sponging microRNA-485-5p and consequently increasing expression of FLOT1 expression

et al. 2021

View full text Add to dashboard Cite

lncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment

Jin

Huang

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Breast cancer is a malignant tumor that has a high mortality rate and mostly occurs in women. Although significant progress has been made in the implementation of personalized treatment strategies for molecular subtypes in breast cancer, the therapeutic response is often not satisfactory. Studies have reported that long non-coding RNAs (lncRNAs) are abnormally expressed in breast cancer and closely related to the occurrence and development of breast cancer. In addition, the high tissue and cell-type specificity makes lncRNAs particularly attractive as diagnostic biomarkers, prognostic factors, and specific therapeutic targets. Therefore, an in-depth understanding of the regulatory mechanisms of lncRNAs in breast cancer is essential for developing new treatment strategies. In this review, we systematically elucidate the general characteristics, potential mechanisms, and targeted therapy of lncRNAs and discuss the emerging functions of lncRNAs in breast cancer. Additionally, we also highlight the advantages and challenges of using lncRNAs as biomarkers for diagnosis or therapeutic targets for drug resistance in breast cancer and present future perspectives in clinical practice.Long non-coding RNAs (lncRNAs) are originally thought to be the noise of transcripts in the genome and have no biological function. Recently, the function of lncRNAs is beginning to attract widespread attention. 7 Increasing studies have shown that lncRNAs are involved in various aspects of cellular physiological processes, such as proliferation, differentiation, migration, and apoptosis, by regulating gene transcription and post-transcriptional processing. 8,9 In addition, lncRNAs are closely related to the occurrence, development, and prognosis of various cancers, such as breast, liver, colon, and lung cancer and even leukemia. [10][11][12][13] According to lncRNA genomic position, subcellular localization, and function, they can be divided into six types (Figure 1). 14 (1) Enhancer lncRNAs are derived from the promoter enhancer region, such as lncRNA-LEENE. 15 (2) Intron lncRNAs are transcribed from the intron region of the gene. The gene-coding protein completely contained the intron lncRNA, which can stabilize the transcription or regulate the alternative splicing of the coding gene. (3) Antisense lncRNA: its transcription orientation is opposite to the transcription orientation of the adjacent protein-encoding gene, such as lncTALAM1 and PDCD4-AS1. 16,17 (4) The sense lncRNA: its transcription orientation is the same as that of the adjacent protein-encoding gene, such as lncRNAGAS5 and ecCEPBA. 18,19 (5) Intergenic lncRNA, which can be transcribed between two protein-coding genes, is an autonomously transcribed

show abstract

Long Noncoding RNAs Involved in the Endocrine Therapy Resistance of Breast Cancer

Cited by 15 publications

References 128 publications

Long Non-coding RNAs Involved in Metabolic Alterations in Breast and Prostate Cancers

Long Non-coding RNAs Involved in Metabolic Alterations in Breast and Prostate Cancers

Long non-coding RNA A1BG-AS1 promotes tumorigenesis in breast cancer by sponging microRNA-485-5p and consequently increasing expression of FLOT1 expression

lncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment

Contact Info

Product

Resources

About